In this new Neuroview in @NeuroCellPress, I discuss "How COVID-19 has transformed my science”. Recounting my personal journey of how I responded to the pandemic, and how the pandemic has transformed the way I do science. Some lessons learned. (1/n)
Glad to highlight my amazing colleagues who made team science possible. The Yale IMPACT team, Albert Ko, @SaadOmer3@NathanGrubaugh@ShelFarFar @CharleszYaleMed @EllenFoxman Allison Nelson & many others. @wade_schulz opened my 👀 to the power of data science (2/)
Yale IMPACT team made quite a contribution on our understanding of viral transmission, detection, disease and immunology behind COVID-19. @EricTopol says it best👇🏽 (3/)
I also learn a lot from being interviewed. My interest in #LongCovid research was sparked by @edyong209, who first interviewed me about this in June 2020. Ed’s articles also led me to @PutrinoLab whom we collaborate with to understand #longCOVID pathogenesis. (4/)
I had a whole section on 🐭 models of COVID and discoveries made by @BenIsraelow@ericsongg@tianyangmao which got deleted due to space limitation. So here I highlight them (6/)
Lesson learned: if I had to do it over again, one thing I would change would be to put my own mental health above other priorities from the beginning. My mistake was not realizing how much of this stress was impacting my own health. #MentalHealthMatters (7/)
I am sooooo fortunate to work with such talented, brilliant, dedicated and kind people in the lab who are making important discoveries daily. I am super proud of you all 💪🏼💜 (8/)
My final thoughts about moving forward. I plan to keep #scicomm a priority. #VaccinesSaveLives
I am committed to advocating for #WomenInSTEM and to help promote more equitable and diverse scientific environment for the next generations to come. Thanks for reading 🙏🏼 (End)
Also, very fortunate to collaborate with @Aaronmring. His REAP technology has transformed our understanding of autoantibodies in COVID. We continue to partner with Aaron and his team to understand the role of autoantibodies. (5b/) pubmed.ncbi.nlm.nih.gov/34010947/
How do the various mutations within the SARS-CoV-2 variants impact vaccine-induced immunity? The amazing @carolilucas@VogelsChantal@InciYildirim11 led this study with with help from others to tackle this question - using 18 CoV-2 variants. (1/n)
The study was designed to measure antibody and T cell immunity from people who were previously infected or not infected with SARS-CoV-2, before and after the 1st and 2nd doses of mRNA vaccines. Amazing effort by @InciYildirim11@SaadOmer3 (2/n)
Antibodies to the ancestral S1 and RBD were induced in both prev. infected and uninfected vaccinees. S/S1/RBD-specific IgG levels in response to vaccination were significantly higher in the previously infected compared to uninfected, as reported by others. (3/n)
This thread is about alpha-gal syndrome (AGS) - meat allergy induced by tick bites. I’ve been living with AGS for >2 yrs. I hope this info will help those who suffer from this illness without knowing the cause. Please help bring awareness to #AGS (1/n)
I live in New England USA, surrounded by beautiful nature. This nature is rich in wildlife - animals and arthropods including many species of ticks. (2/n)
Ticks are infamous for the many infectious agents they carry that cause diseases such as
Latest preprint by @tianyangmao et al shows that a stem-loop RNA RIG-I agonist in mice can
1) Block viral replication and disease when given early after SARS-CoV-2 infection (including VOCs)
2)Eliminate chronic infection in immunodeficient mice
We urgently need antiviral agents that can work against any viral threats. Here, we use a stem-loop RNA developed by @AnnaPyle to trigger interferon to stimulate antiviral state. Work by @MelissaLV14 et al demonstrated robust ISG induction in mice👇🏽 (2/)
First, we wanted to know if SLR can be used as a post-exposure prophylaxis. Mice infected with lethal dose of SARS-CoV-2 were treated with SLR 4 hours after exposure. SLR-treated mice had no detectable infectious virus 5 days later and most survived. (3/)
It’s finally happening! I will be giving a talk today at the #AAI2021 with Dr. Fauci and Dr. Saif in the session, COVID-19 and the Science of Pandemics (12-2PM ET).
My talk will be on “Protective vs. harmful immune responses in COVID-19”. See you there!
Amazing to listen to Dr. Fauci talk about the decades of basic research that led to the success of COVID vaccines. #AAI2021
“Effectiveness of the vaccines in real world setting is stunning - in every single age group.”
Exciting talk by Dr. Saif focuses on all things mucosal immunity! Secretory IgA, tissue-resident memory B cells and T cells are key to confer durable mucosal immunity. #AAI2021
SARS-CoV-2 infects not only respiratory mucosa, but also found in the gut, eyes and oral cavity.
This study will examine how vaccines might improve the symptoms of #LongCovid. We are recruiting people with long covid (PCR+, Ab+, T-test+, or COVID diagnosed by medical doctor) who live in Connecticut, >18 years old, and have not received vaccines yet but are planning to. (2/n)
To participate in this study, you will be asked to complete 4 online surveys and provide blood and saliva 3 times at sites in New Haven Connecticut. If you are interested in participating, please email covidrecovery@yale.edu (3/n)
New study by @MHitchingsEpi et al shows that an inactivated vaccine CoronaVac is effective against COVID-19 in a setting of epidemic P.1 variant transmission in Brazil 🇧🇷. A thread. (1/n)
The authors conducted a matched test-negative case-control study to estimate the effectiveness of an
inactivated vaccine, CoronaVac, in healthcare workers in Manaus, where P.1 accounted for ~75% of the circulating virus.(2/n)
Vaccination with at least one dose was associated with an adjusted vaccine effectiveness of 49.6% (95% CI, 11.3 - 71.4) against symptomatic SARSCoV-2 infection >14 days after receiving the first dose. (3/n)